Case Details

CourtDistrict of Delaware
Docket number1:13-cv-00978
Date case filed2013-06-04
Date case closed2016-08-18
Date of latest filing
Assigned toJudge Richard G. Andrews
Case cause35:271 Patent Infringement
Nature of suit830 Patent
Jury demandNone
Demand
JurisdictionFederal Question

Case Parties

Party: Merck & Cie
Party type: Counter Defendant
Attorney name: Jack B. Blumenfeld
Attorney Contact:
(See above for address)
LEAD ATTORNEY ATTORNEY TO BE NOTICED

Attorney name: Rodger Dallery Smith , II
Attorney Contact:
(See above for address)
ATTORNEY TO BE NOTICED
Party: Bayer Pharma AG
Party type: Counter Defendant
Attorney name: Jack B. Blumenfeld
Attorney Contact:
(See above for address)
LEAD ATTORNEY ATTORNEY TO BE NOTICED

Attorney name: Rodger Dallery Smith , II
Attorney Contact:
(See above for address)
ATTORNEY TO BE NOTICED
Party: Bayer HealthCare Pharmaceuticals Inc.
Party type: Counter Defendant
Attorney name: Jack B. Blumenfeld
Attorney Contact:
(See above for address)
LEAD ATTORNEY ATTORNEY TO BE NOTICED

Attorney name: Rodger Dallery Smith , II
Attorney Contact:
(See above for address)
ATTORNEY TO BE NOTICED
Party: Watson Laboratories Inc.
Party type: Counter Claimant
Attorney name: David Ellis Moore
Attorney Contact:
(See above for address)
ATTORNEY TO BE NOTICED
Party: Actavis Inc.
Party type: Defendant
TERMINATED: 07/31/2013
Attorney name: Richard L. Horwitz
Attorney Contact:
(See above for address)
TERMINATED: 07/31/2013 LEAD ATTORNEY ATTORNEY TO BE NOTICED

Case Docket

Docket
Item
Date FiledDocument
Available
Short
Description
Long Description
12013-06-04 COMPLAINT FOR PATENT INFRINGEMENT - filed against Actavis Inc., Watson Laboratories Inc. - Magistrate Consent Notice to Pltf. ( Filing fee $ 400.00, receipt number 0311-1302652.) - filed by Merck & Cie, Bayer Pharma AG, Bayer HealthCare Pharmaceuticals Inc.. (Attachments: # 1 Exhibit 1, # 2 Civil Cover Sheet)(rwc) (Entered: 06/04/2013)
1.1 Exhibit 1
1.2 Civil Cover Sheet
22013-06-04 Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction (rwc) (Entered: 06/04/2013)
32013-06-04 Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 4/24/13. Date of Expiration of Patent: 4/17/20.Thirty Month Stay Deadline: 10/24/2015. (rwc) (Entered: 06/04/2013)
42013-06-04 Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 6,441,168 B1. (rwc) (Entered: 06/04/2013)
52013-06-04 Disclosure Statement pursuant to Rule 7.1 filed by Bayer HealthCare Pharmaceuticals Inc., Bayer Pharma AG, Merck & Cie identifying Corporate Parent Merck KGaA for Merck & Cie; Corporate Parent Bayer AG for Bayer HealthCare Pharmaceuticals Inc., Bayer Pharma AG. (rwc) (Entered: 06/04/2013)
62013-06-14 DECLARATION of Mailing as to service on all defendants, by Bayer HealthCare Pharmaceuticals Inc., Bayer Pharma AG, Merck & Cie. (Attachments: # 1 Exhibits A - D)(Noreika, Maryellen) Modified on 6/17/2013 (nms). (Entered: 06/14/2013)
72013-07-09 STIPULATION TO EXTEND TIME to answer, move or otherwise respond to the Complaint to August 2, 2013 - filed by Actavis Inc., Watson Laboratories Inc.. (Horwitz, Richard) (Entered: 07/09/2013)
82013-07-19 MOTION for Pro Hac Vice Appearance of Attorney Adam K. Mortara, J. Scott McBride, and Asha L.I. Spencer of BARTLIT BECK HERMAN PALENCHAR &SCOTT LLP - filed by Bayer HealthCare Pharmaceuticals Inc., Bayer Pharma AG, Merck & Cie. (Blumenfeld, Jack) (Entered: 07/19/2013)
92013-07-31 STIPULATION of Dismissal, by Actavis Inc., Watson Laboratories Inc.. (Moore, David) Modified on 7/31/2013 (nms). (Entered: 07/31/2013)
102013-07-31 SO ORDERED re 9 Stipulation of Dismissal as to Defendant Actavis Inc., filed by Actavis Inc., Watson Laboratories Inc. (Actavis Inc. terminated). Signed by Judge Richard G. Andrews on 7/31/2013. (nms) (Entered: 07/31/2013)
112013-08-02 ANSWER to 1 Complaint, Defenses, COUNTERCLAIM against All Plaintiffs by Watson Laboratories Inc..(Moore, David) (Entered: 08/02/2013)
122013-08-02 Disclosure Statement pursuant to Rule 7.1 filed by Watson Laboratories Inc. identifying Corporate Parent Actavis, Inc. for Watson Laboratories Inc... (Moore, David) (Entered: 08/02/2013)
132013-08-19 Supplemental Disclosure Statement pursuant to Rule 7.1 filed by Watson Laboratories Inc. identifying Corporate Parent Actavis, Inc. for Watson Laboratories Inc... (Moore, David) (Entered: 08/19/2013)
142013-08-20 Order Setting Rule 16(b) Conference: A Scheduling Conference is set for 10/11/2013, at 1:30 PM in Chambers before Judge Richard G. Andrews (see Order for further details). Signed by Judge Richard G. Andrews on 8/20/2013. (nms) (Entered: 08/20/2013)
152013-08-23 ANSWER to 11 Answer to Complaint, Counterclaim by Bayer HealthCare Pharmaceuticals Inc., Bayer Pharma AG, Merck & Cie.(Blumenfeld, Jack) (Entered: 08/23/2013)
162013-08-27 MOTION for Pro Hac Vice Appearance of Attorney Steven A. Maddox, Jeremy J. Edwards and Andrea L. Cheek of Knobbe, Martens, Olson & Bear, LLP - filed by Watson Laboratories Inc.. (Palapura, Bindu) (Entered: 08/27/2013)
172013-10-08 PROPOSED Schdeduling Order, by Bayer HealthCare Pharmaceuticals Inc., Bayer Pharma AG, Merck & Cie, Watson Laboratories Inc.. (Attachments: # 1 Letter)(Blumenfeld, Jack) Modified on 10/9/2013 (nms). (Entered: 10/08/2013)
182013-10-08 NOTICE OF SERVICE of Defendant Watson Laboratories, Inc.'s First Set of Requests for the Production of Documents and Things (Nos. 1-130); and Defendant Watson Laboratories, Inc.'s First Set of Interrogatories (Nos. 1-13) by Watson Laboratories Inc..(Moore, David) (Entered: 10/08/2013)
192013-10-08 NOTICE OF SERVICE of (1) Plaintiffs' First Set of Interrogatories to Defendant Watson Laboratories, Inc. and (2) Plaintiffs' First Set of Requests for Production of Documents and Things to Defendant Watson Laboratories, Inc. by Bayer HealthCare Pharmaceuticals Inc., Bayer Pharma AG, Merck & Cie.(Blumenfeld, Jack) (Entered: 10/08/2013)
202013-10-21 PROPOSED Scheduling Order, by Actavis Inc., Bayer HealthCare Pharmaceuticals Inc., Bayer Pharma AG, Merck & Cie, Watson Laboratories Inc., 911 Notify LLC, Everbridge Inc.. (Attachments: # 1 Letter)(Blumenfeld, Jack) Modified on 10/22/2013 (nms). (Entered: 10/21/2013)
212013-10-22 SCHEDULING ORDER: Case referred to the Magistrate Judge for the purpose of exploring ADR. Joinder of Parties due by 4/23/2014. Amended Pleadings due by 4/23/2014. Joint Claim Construction Brief due by 5/14/2014. A Markman Hearing is set for 5/29/2014, at 8:30 AM in Courtroom 6A before Judge Richard G. Andrews. A Pretrial Conference is set for 12/12/2014, at 8:30 AM in Courtroom 6A before Judge Richard G. Andrews. A Bench Trial is set for 1/5/2015, at 9:30 AM in Courtroom 6A before Judge Richard G. Andrews (see Order for further details). Signed by Judge Richard G. Andrews on 10/22/2013. Associated Cases: 1:13-cv-01272-RGA, 1:13-cv-00978-RGA(nms) (Entered: 10/22/2013)
222013-10-23 ORDER Setting Teleconference: Counsel for Merck to initiate the call. A Telephone Conference is set for 12/16/2013 at 11:00 AM EASTERN TIME before Judge Mary Pat Thynge to discuss ADR. Signed by Judge Mary Pat Thynge on 10/23/13. (cak) (Entered: 10/23/2013)
232013-10-28 NOTICE OF SERVICE of Watson's Initial Disclosures Pursuant to Fed. R. Civ. P. 26(a)(1) by Watson Laboratories Inc..(Palapura, Bindu) (Entered: 10/28/2013)
242013-10-28 NOTICE OF SERVICE of Plaintiffs' Initial Disclosures by Bayer HealthCare Pharmaceuticals Inc., Bayer Pharma AG, Merck & Cie.(Blumenfeld, Jack) (Entered: 10/28/2013)
252013-11-01 MOTION for Pro Hac Vice Appearance of Attorney Rebecca T. Horwitz - filed by Bayer HealthCare Pharmaceuticals Inc., Bayer Pharma AG, Merck & Cie. (Blumenfeld, Jack) (Entered: 11/01/2013)
262013-11-01 PROPOSED Protective Order, by Bayer HealthCare Pharmaceuticals Inc., Bayer Pharma AG, Merck & Cie. (Blumenfeld, Jack) Modified on 11/4/2013 (nms). (Entered: 11/01/2013)
272013-11-04 SO ORDERED re (25 in 1:13-cv-01272-RGA, 26 in 1:13-cv-00978-RGA) Proposed Protective Order, filed by Bayer HealthCare Pharmaceuticals Inc., Bayer Pharma AG, Merck & Cie. Signed by Judge Richard G. Andrews on 11/4/2013. Associated Cases: 1:13-cv-01272-RGA, 1:13-cv-00978-RGA(nms) (Entered: 11/04/2013)
282013-11-05 Amended Disclosure Statement pursuant to Rule 7.1 filed by Watson Laboratories Inc. identifying Corporate Parent Actavis, Inc. for Watson Laboratories Inc... (Moore, David) (Entered: 11/05/2013)
292013-11-07 NOTICE Of Service of Defendant Watson Laboratories, Inc.'S Objections and Responses to First Set of Interrogatories (Nos. 1-3); and Defendant Watson Laboratories, Inc.'S Objections and Responses to Plaintiffs' First Set of Requests for the Production of Documents and Things (NOS. 1-54), by Watson Laboratories Inc..(Moore, David) Modified on 11/8/2013 (nms). (Entered: 11/07/2013)
302013-11-12 NOTICE OF SERVICE of Defendant Watson Laboratories, Inc.'s Initial Disclosures Pursuant to Paragraph 3 of the Delaware Default Standard for Discovery [Highly Confidential] by Watson Laboratories Inc..(Moore, David) (Entered: 11/12/2013)
312013-11-12 NOTICE OF SERVICE of (1) Plaintiffs' Answers to Defendant Watson Laboratories, Inc.'s First Set of Interrogatories (Nos. 1-13); (2) Plaintiffs' Responses to Defendant Watson Laboratories, Inc.'s First Set of Requests for the Production of Documents and Things (Nos. 1-130); and (3) Plaintiffs' Initial Disclosures Pursuant to Paragraph 3(a) of the Scheduling Order by Bayer HealthCare Pharmaceuticals Inc., Bayer Pharma AG, Merck & Cie.(Smith, Rodger) (Entered: 11/12/2013)
322013-11-18 NOTICE OF SERVICE of Plaintiffs' Initial Claim Chart by Bayer HealthCare Pharmaceuticals Inc., Bayer Pharma AG, Merck & Cie.(Smith, Rodger) (Entered: 11/18/2013)
332013-12-05 MOTION for Pro Hac Vice Appearance of Attorney Jonathan E. Bachand - filed by Watson Laboratories Inc.. (Moore, David) (Entered: 12/05/2013)
342013-12-18 NOTICE OF SERVICE of Defendant's Initial Invalidity Contentions filed by Watson Laboratories Inc..(Palapura, Bindu) (Entered: 12/18/2013)
352014-01-23 NOTICE OF SERVICE of Defendant's List Of Terms To Be Construed And Proposed Constructions filed by Watson Laboratories Inc..(Palapura, Bindu) (Entered: 01/23/2014)
362014-02-14 STIPULATION TO EXTEND TIME for parties to submit Joint Claim Chart to February 21, 2014 - filed by Bayer HealthCare Pharmaceuticals Inc., Bayer Pharma AG, Merck & Cie, Watson Laboratories Inc.. (Blumenfeld, Jack) (Entered: 02/14/2014)
372014-02-19 STIPULATION and Order Regarding Infringement and Claim Construction by Bayer HealthCare Pharmaceuticals Inc., Bayer Pharma AG, Merck & Cie. (Blumenfeld, Jack) (Entered: 02/19/2014)
382014-02-19 ORDER Regarding Infringement and Claim Construction of U.S. Patent NO. 6,441,168 (*the May 29,2014, Markman hearing has been removed from the Court calendar). Signed by Judge Richard G. Andrews on 2/19/2014. Associated Cases: 1:13-cv-00978-RGA, 1:13-cv-01272-RGA(nms) (Entered: 02/19/2014)
392014-04-16 NOTICE to Take Deposition of Merck & Cie, Bayer Pharma AG and Bayer Healthcare Pharmaceuticals, Inc. pursuant to Fed. R. Civ. P. 30(b)(6) on May 23, 2014 filed by Watson Laboratories Inc..(Palapura, Bindu) (Entered: 04/16/2014)
402014-04-16 NOTICE OF SERVICE of Watson's Second Set of Interrogatories to Plaintiffs (Nos. 14-16) and Watson's Objections and Supplemental Response to First Set of Interrogatories (No. 2) filed by Watson Laboratories Inc..(Palapura, Bindu) (Entered: 04/16/2014)
412014-04-18 NOTICE OF SERVICE of Plaintiffs' First Supplemental Responses and Objections to Defendant Watson Laboratories, Inc.'s First Set of Interrogatories (Nos. 1-13) filed by Bayer HealthCare Pharmaceuticals Inc., Bayer Pharma AG, Merck & Cie.(Blumenfeld, Jack) (Entered: 04/18/2014)
422014-04-23 STIPULATION AND ORDER Extending Dates in Scheduling Order, by Watson Laboratories Inc.. (Horwitz, Richard) Modified on 4/24/2014 (nms). (Entered: 04/23/2014)
432014-05-06 NOTICE OF SERVICE of Plaintiffs' Second Supplemental Responses and Objections to Defendant Watson Laboratories, Inc.'s First Set of Interrogatories (Nos. 1-13) filed by Bayer HealthCare Pharmaceuticals Inc., Bayer Pharma AG, Merck & Cie.(Smith, Rodger) (Entered: 05/06/2014)
442014-05-08 NOTICE OF SERVICE of Defendant Watson Laboratories, Inc.'s Second Set of Requests for the Production of Documents and Things (Nos. 131-150) filed by Watson Laboratories Inc..(Moore, David) (Entered: 05/08/2014)
452014-05-16 NOTICE OF SERVICE of Plaintiffs' Responses to Defendant Watson Laboratories, Inc.'s Second Set of Interrogatories (Nos. 14-16) filed by Bayer HealthCare Pharmaceuticals Inc., Bayer Pharma AG, Merck & Cie.(Blumenfeld, Jack) (Entered: 05/16/2014)
462014-05-21 NOTICE OF SERVICE of Bayer's Objections and Responses to Defendant Watson's Notice of Deposition to Plaintiffs Pursuant to Rule 30(b)(6) filed by Bayer HealthCare Pharmaceuticals Inc., Bayer Pharma AG, Merck & Cie.(Blumenfeld, Jack) (Entered: 05/21/2014)
472014-05-28 NOTICE Of Service of Defendant Watson Laboratories, Inc.'S Third Set of Interrogatories to Plaintiffs (NOS. 17-20), filed by Watson Laboratories Inc..(Moore, David) Modified on 5/28/2014 (nms). (Entered: 05/28/2014)
482014-06-05 NOTICE OF SERVICE of Defendant Watson Laboratories, Inc.'s Fourth Set of Interrogatories to Plaintiffs (No. 21) filed by Watson Laboratories Inc..(Struble, Erich) (Entered: 06/05/2014)
492014-06-11 NOTICE of Issuance of Subpoenas on University of Alabama, Department of Pharmacology and Pfizer by Watson Laboratories Inc. (Attachments: # 1 Exhibit 1-4)(Struble, Erich) (Entered: 06/11/2014)
502014-06-12 NOTICE OF SERVICE of Plaintiffs' Reponses to Defendant Watson Laboratories, Inc.'s Second Set of Requests for the Production of Documents and Things (Nos. 131-150) filed by Bayer HealthCare Pharmaceuticals Inc., Bayer Pharma AG, Merck & Cie.(Fahnestock, Derek) (Entered: 06/12/2014)
512014-06-16 MOTION for Pro Hac Vice Appearance of Attorney Christie R.W. Matthaei of Knobbe, Martens, Olson & Bear, LLP - filed by Watson Laboratories Inc.. (Struble, Erich) (Entered: 06/16/2014)
522014-06-25 SECOND NOTICE to Take Deposition of Merck & Cie, Bayer Pharma AG and Bayer Healthcare Pharmaceuticals, Inc. on July 8, 2014, filed by Watson Laboratories Inc..(Horwitz, Richard) Modified on 6/25/2014 (nms). (Entered: 06/25/2014)
532014-06-27 NOTICE OF SERVICE of Plaintiffs' Responses to Defendant Watson Laboratories, Inc.'s Third Set of Interrogatories (Nos. 17-20) filed by Bayer HealthCare Pharmaceuticals Inc., Bayer Pharma AG, Merck & Cie.(Fahnestock, Derek) (Entered: 06/27/2014)
542014-07-07 NOTICE OF SERVICE of (1) Plaintiffs' Objections and Responses to Defendant Watson's Second Notice of Deposition to Plaintiffs Pursuant to Rule 30(b)(6); and (2) Plaintiffs' Responses to Defendant Watson Laboratories, Inc.'s Fourth Set of Interrogatories (No. 21) filed by Bayer HealthCare Pharmaceuticals Inc., Bayer Pharma AG, Merck & Cie.(Fahnestock, Derek) (Entered: 07/07/2014)
552014-07-08 ORAL ORDER: Pursuant to the parties request the Court will hold a Telephone Conference 7/9/2014, at 1:30 PM before Judge Richard G. Andrews. Watsons' counsel shall coordinate the call to the Court. Ordered by Judge Richard G. Andrews on 7/8/2014. Associated Cases: 1:13-cv-00978-RGA, 1:13-cv-01272-RGA(nms) (Entered: 07/08/2014)
562014-07-10 STIPULATION extending certain dates by Watson Laboratories Inc.. (Struble, Erich) (Entered: 07/10/2014)
572014-07-10 SO ORDERED Granting (56 in 1:13-cv-01272-RGA, 56 in 1:13-cv-00978-RGA) Stipulation and Order Extending Dates (Reset Deadlines/Hearings: Fact Discovery due by 10/31/2014, A Bench Trial is set for 5/18/2015, at 9:00 AM in Courtroom 6A before Judge Richard G. Andrews, A Pretrial Conference is set for 5/8/2015, at 8:30 AM in Courtroom 6A before Judge Richard G. Andrews). Signed by Judge Richard G. Andrews on 7/10/2014. Associated Cases: 1:13-cv-00978-RGA, 1:13-cv-01272-RGA(nms) (Entered: 07/10/2014)
582014-07-16 NOTICE of Issuance of Subpoenas on Meduski Research Corporation, Metagenics, Inc. and Weider Global Nutrition, LLC by Watson Laboratories Inc. (Moore, David) (Entered: 07/16/2014)
592014-07-25 NOTICE of Withdrawal of Erich W. Struble, formerly of Potter Anderson & Corroon LLP by Watson Laboratories Inc. (Moore, David) (Entered: 07/25/2014)
602014-07-29 NOTICE of Issuance of Subpoena upon Reckitt Benckiser, LLC by Watson Laboratories Inc. (Moore, David) (Entered: 07/29/2014)
612014-09-02 NOTICE of Change of Firm Address (Knobbe, Martens, Olson & Bear, LLP-Seattle Office) by Watson Laboratories Inc. (Moore, David) (Entered: 09/02/2014)
622014-09-19 NOTICE to Take Deposition of Third Notice of Deposition of Merck & Cie, Bayer Pharma AG and Bayer Healthcare Pharmaceuticals, Inc. Pursuant to Fed. R. Civ. P. 30(b)(6) on October 1, 2014 filed by Watson Laboratories Inc..(Moore, David) (Entered: 09/19/2014)
632014-09-30 NOTICE OF SERVICE of Watson's Objections and Supplemental Responses to First Set of Interrogatories (Nos. 1 & 3) and Second Supplemental Responses to First Set of Interrogatories (No. 2) (Confidential) and Watson's Supplemental Invalidity Contentions (Confidential) filed by Watson Laboratories Inc..(Moore, David) (Entered: 09/30/2014)
642014-09-30 MOTION for Pro Hac Vice Appearance of Attorney Andrew C. MacNally - filed by Bayer HealthCare Pharmaceuticals Inc., Bayer Pharma AG, Merck & Cie. (Fahnestock, Derek) (Entered: 09/30/2014)
652014-10-01 NOTICE OF SERVICE of Plaintiffs' Second Set of Interrogatories to Defendant Watson Laboratories, Inc. filed by Bayer HealthCare Pharmaceuticals Inc., Bayer Pharma AG, Merck & Cie.(Fahnestock, Derek) (Entered: 10/01/2014)
662014-10-07 MOTION for Pro Hac Vice Appearance of Attorney Katharine A. Roin - filed by Bayer HealthCare Pharmaceuticals Inc., Bayer Pharma AG, Merck & Cie. (Blumenfeld, Jack) (Entered: 10/07/2014)
672014-10-13 NOTICE OF SERVICE of (1) Plaintiffs' Objections and Responses to Defendant Watson's Third Notice of Deposition to Plaintiffs Pursuant to Rule 30(b)(6); and (2) Plaintiffs' Supplemental Responses to Watson's Interrogatories (Nos. 4, 5, 16, 18, 21) filed by Bayer HealthCare Pharmaceuticals Inc., Bayer Pharma AG, Merck & Cie.(Blumenfeld, Jack) (Entered: 10/13/2014)
682014-10-13 NOTICE of Issuance of Subpoenas upon Reckitt Benckiser, LLC and Michele Sly by Watson Laboratories Inc. (Moore, David) (Main Document 68 replaced on 10/14/2014) (nms). (Entered: 10/13/2014)
692014-10-15 NOTICE of Issuance of Subpoena upon Luke Bucci by Watson Laboratories Inc. (Moore, David) (Entered: 10/15/2014)
702014-10-31 NOTICE OF SERVICE of (1) Plaintiffs' Third Supplemental Responses to Watson's Interrogatory No. 5 and (2) Plaintiffs' First Amended Initial Disclosures filed by Bayer HealthCare Pharmaceuticals Inc., Bayer Pharma AG, Merck & Cie.(Fahnestock, Derek) (Entered: 10/31/2014)
712014-10-31 NOTICE OF SERVICE of Defendant Watson Laboratories, Inc.'s Objections and Third Supplemental Responses to First Set of Interrogatories (No. 2) [Confidential - Pursuant to Protective Order] and Defendant Watson Laboratories, Inc.'s Objections and Responses to Plaintiffs' Second Set of Interrogatories (Nos. 4-6) [Confidential - Pursuant to Protective Order] filed by Watson Laboratories Inc..(Palapura, Bindu) (Entered: 10/31/2014)
722014-11-05 [SEALED] STIPULATION regarding ESF-118 by Watson Laboratories Inc.. (Horwitz, Richard) (Entered: 11/05/2014)
732014-11-05 [SEALED] SO ORDERED re (D.I. 72 in 13-cv-00978-RGA, D.I. 72 in 13-cv-01272-RGA) Stipulation and Order Regarding ESF-118, filed by Watson Laboratories Inc.. Signed by Judge Richard G. Andrews on 11/5/2014.This order has been emailed to local counsel. Associated Cases: 1:13-cv-00978-RGA, 1:13-cv-01272-RGA(nms) (Entered: 11/06/2014)
742014-11-12 REDACTED VERSION of 72 Stipulation regarding ESF-118, by Watson Laboratories Inc.. (Horwitz, Richard) Modified on 11/13/2014 (nms). (Entered: 11/12/2014)
752014-11-19 STIPULATION Regarding Authenticity of Business Records by Bayer HealthCare Pharmaceuticals Inc., Bayer Pharma AG, Merck & Cie. (Fahnestock, Derek) (Entered: 11/19/2014)
762014-12-17 [SEALED] Letter to The Honorable Richard G. Andrews from Richard L. Horwitz, Esq. requesting leave to file motion for summary judgment and supporting documents. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C part 1, # 4 Exhibit C part 2, # 5 Exhibit C part 3, # 6 Exhibit C part 4)(Horwitz, Richard) Modified on 12/18/2014 (nms). (Attachment 3 replaced on 12/18/2014) (nms). (Entered: 12/17/2014)
772014-12-18 ORAL ORDER: Plaintiffs directed to respond to Watson's December 17, 2014, letter by December 22, 2014, response to include the identification of any disputed material facts. Ordered by Judge Richard G. Andrews on 12/18/2014. Associated Cases: 1:13-cv-00978-RGA, 1:13-cv-01272-RGA(nms) (Entered: 12/18/2014)
782014-12-22 [SEALED] Letter to The Honorable Richard G. Andrews from Jack B. Blumenfeld responding to Watson's December 17, 2014 Letter and the Court's December 18, 2014 Order. (Attachments: # 1 Exhibits A-S)(Blumenfeld, Jack) Modified on 12/22/2014 (nms). (Entered: 12/22/2014)
792014-12-23 ORDER Denying Defendant's request for leave to file a summary judgment motion. Signed by Judge Richard G. Andrews on 12/23/2014. Associated Cases: 1:13-cv-00978-RGA, 1:13-cv-01272-RGA(nms) (Entered: 12/23/2014)
802014-12-23 REDACTED VERSION of 76 Letter, by Watson Laboratories Inc.. (Attachments: # 1 Exhibits A-B, # 2 Exhibit C, # 3 Exhibit 1-50 of Ex C)(Horwitz, Richard) Modified on 1/4/2015 (nms). (Entered: 12/23/2014)
812014-12-29 REDACTED VERSION of 78 Letter, by Bayer HealthCare Pharmaceuticals Inc., Bayer Pharma AG, Merck & Cie. (Attachments: # 1 Exhibits A-S)(Blumenfeld, Jack) Modified on 1/4/2015 (nms). (Entered: 12/29/2014)
822015-01-12 NOTICE OF SERVICE of Expert Report of Robin Rogers, Ph.D. [Confidential] and Expert Report of Jeremiah A. Marsden [Confidential] filed by Watson Laboratories Inc..(Palapura, Bindu) (Entered: 01/12/2015)
832015-01-22 NOTICE of of Change of Firm Affiliation and Withdrawal of Counsel by Watson Laboratories Inc. (Palapura, Bindu) (Entered: 01/22/2015)
842015-02-06 NOTICE OF SERVICE of (1) Expert Rebuttal Report of Professor Allan S. Myerson, Ph.D.and (2) Expert Rebuttal Report of Dr. Lee P. Shulman, M.D. filed by Bayer HealthCare Pharmaceuticals Inc., Bayer Pharma AG, Merck & Cie.(Fahnestock, Derek) (Entered: 02/06/2015)
852015-03-06 NOTICE OF SERVICE of Reply Expert Report of Robin D. Rogers, Ph.D. [Confidential] filed by Watson Laboratories Inc..(Horwitz, Richard) (Entered: 03/06/2015)
862015-03-06 NOTICE of Change of Firm Affiliation by Watson Laboratories Inc. (Moore, David) (Entered: 03/06/2015)
872015-03-12 ORAL ORDER: Due to a scheduling conflict the Pretrial Conference set for 5/8/2015, will now commence at 3:00 PM in Courtroom 6A before Judge Richard G. Andrews. Ordered by Judge Richard G. Andrews on 3/12/2015. Associated Cases: 1:13-cv-00978-RGA, 1:13-cv-01272-RGA(nms) (Entered: 03/12/2015)
882015-04-02 MOTION for Pro Hac Vice Appearance of Attorney Faye E. Paul of Bartlit Beck Herman Palenchar & Scott LLP - filed by Bayer Pharma AG, Merck & Cie, Bayer HealthCare Pharmaceuticals Inc.. (Fahnestock, Derek) (Entered: 04/02/2015)
892015-04-23 MOTION for Pro Hac Vice Appearance of Attorney Matthew C. Ruedy of Maddox Edwards, PLLC - filed by Watson Laboratories Inc.. (Moore, David) (Entered: 04/23/2015)
902015-05-05 [SEALED] Proposed Pretrial Order, by Bayer HealthCare Pharmaceuticals Inc., Bayer Pharma AG, Merck & Cie. (Attachments: # 1 Exhibits 1-15, # 2 Exhibits 16-17)(Fahnestock, Derek) Modified on 5/6/2015 (nms). (Entered: 05/05/2015)
912015-05-08 ORDER After Pretrial Conference (see Order for further details). Signed by Judge Richard G. Andrews on 5/8/2015. Associated Cases: 1:13-cv-00978-RGA, 1:13-cv-01272-RGA(nms) (Entered: 05/08/2015)
922015-05-12 REDACTED VERSION of 90 Proposed Pretrial Order, by Bayer HealthCare Pharmaceuticals Inc., Bayer Pharma AG, Merck & Cie. (Attachments: # 1 Exhibits 1-15, # 2 Exhibits 16-17)(Fahnestock, Derek) Modified on 5/12/2015 (nms). (Entered: 05/12/2015)
932015-05-13 NOTICE OF SERVICE of Supplemental Expert Report of Professor Allan S. Myerson, Ph.D. filed by Bayer HealthCare Pharmaceuticals Inc., Bayer Pharma AG, Merck & Cie.(Blumenfeld, Jack) (Entered: 05/13/2015)
942015-05-15 NOTICE OF SERVICE of Supplemental Reply Expert Report of Robin D. Rogers, Ph.D. (with Exhibit) [Confidential] filed by Watson Laboratories Inc..(Palapura, Bindu) (Entered: 05/15/2015)
952015-05-21 Witness List from Bench Trial held 5/18/2015 - 5/21/2015. (ksr, ) (Entered: 05/21/2015)
962015-05-29 NOTICE of Lodging of Watson Laboratories, Inc.'s Trial Exhibits Admitted During the Bench Trial Held May 18-21, 2015 by Watson Laboratories Inc. (Moore, David) (Additional attachment(s) added on 6/1/2015: # 1 Exhibit List) (nms). (Entered: 05/29/2015)
972015-05-29 NOTICE of Lodging of Admitted Trial Exhibits by Bayer HealthCare Pharmaceuticals Inc., Bayer Pharma AG, Merck & Cie (Attachments: # 1 Exhibit A)(Fahnestock, Derek) (Entered: 05/29/2015)
982015-06-11 Opening POST TRIAL BRIEF, by Watson Laboratories Inc.. (Moore, David) Modified on 6/12/2015 (nms). (Entered: 06/11/2015)
992015-07-02 [SEALED] Post-Trial Response Brief, by Bayer HealthCare Pharmaceuticals Inc., Bayer Pharma AG, Merck & Cie. (Attachments: # 1 Exhibits A-B)(Fahnestock, Derek) Modified on 7/2/2015 (nms). (Entered: 07/02/2015)
1002015-07-02 REDACTED VERSION of 99 Post-Trial Response Brief, by Bayer HealthCare Pharmaceuticals Inc., Bayer Pharma AG, Merck & Cie. (Attachments: # 1 Exhibits A-B)(Fahnestock, Derek) Modified on 7/2/2015 (nms). (Entered: 07/02/2015)
1012015-07-08 Official Transcript of Pretrial Conference held on 05-08-15 before Judge Richard G. Andrews. Court Reporter/Transcriber Valerie J. Gunning. Transcript may be viewed at the court public terminal or purchased through the Court Reporter/Transcriber before the deadline for Release of Transcript Restriction. After that date it may be obtained through PACER. Redaction Request due 7/29/2015. Redacted Transcript Deadline set for 8/10/2015. Release of Transcript Restriction set for 10/6/2015. (lad) (Entered: 07/08/2015)
1022015-07-15 Official Transcript of Bench Trial (Day 1) held on 05-18-15 before Judge Richard G. Andrews. Court Reporter/Transcriber Valerie J. Gunning. Transcript may be viewed at the court public terminal or purchased through the Court Reporter/Transcriber before the deadline for Release of Transcript Restriction. After that date it may be obtained through PACER. Redaction Request due 8/5/2015. Redacted Transcript Deadline set for 8/17/2015. Release of Transcript Restriction set for 10/13/2015. (lad) (Entered: 07/15/2015)
1032015-07-15 Official Transcript of Bench Trial (Day 2) held on 05-19-15 before Judge Richard G. Andrews. Court Reporter/Transcriber Valerie J. Gunning. Transcript may be viewed at the court public terminal or purchased through the Court Reporter/Transcriber before the deadline for Release of Transcript Restriction. After that date it may be obtained through PACER. Redaction Request due 8/5/2015. Redacted Transcript Deadline set for 8/17/2015. Release of Transcript Restriction set for 10/13/2015. (lad) (Entered: 07/15/2015)
1042015-07-15 Official Transcript of Bench Trial (Day 3) held on 05-20-15 before Judge Richard G. Andrews. Court Reporter/Transcriber Valerie J. Gunning. Transcript may be viewed at the court public terminal or purchased through the Court Reporter/Transcriber before the deadline for Release of Transcript Restriction. After that date it may be obtained through PACER. Redaction Request due 8/5/2015. Redacted Transcript Deadline set for 8/17/2015. Release of Transcript Restriction set for 10/13/2015. (lad) (Entered: 07/15/2015)
1052015-07-15 Official Transcript of Bench Trial (Day 4) held on 05-21-15 before Judge Richard G. Andrews. Court Reporter/Transcriber Valerie J. Gunning. Transcript may be viewed at the court public terminal or purchased through the Court Reporter/Transcriber before the deadline for Release of Transcript Restriction. After that date it may be obtained through PACER. Redaction Request due 8/5/2015. Redacted Transcript Deadline set for 8/17/2015. Release of Transcript Restriction set for 10/13/2015. (lad) (Entered: 07/15/2015)
1062015-07-21 [SEALED] Reply Post-Trial Brief, by Watson Laboratories Inc.. (Attachments: # 1 Exhibits A-B)(Moore, David) Modified on 7/22/2015 (nms). (Entered: 07/21/2015)
1072015-07-21 Letter to The Honorable Richard G. Andrews from David E. Moore, Esq. regarding corrected version of Defendant's Opening Post-Trial Brief. (Attachments: # 1 Exhibit A)(Moore, David) Modified on 7/22/2015 (nms). (Entered: 07/21/2015)
1082015-07-21 Corrected Opening Post-Trial Brief, by Watson Laboratories Inc.. (Moore, David) Modified on 7/22/2015 (nms). (Entered: 07/21/2015)
1092015-07-22 Letter to The Honorable Richard G. Andrews from Derek J. Fahnestock regarding Corrected Post-Trial Response Brief. (Fahnestock, Derek) Modified on 7/22/2015 (nms). (Entered: 07/22/2015)
1102015-07-22 [SEALED] EXHIBIT to (109 in 13-cv-978-RGA, 108 in 13-cv-1272-RGA) Letter, by Bayer HealthCare Pharmaceuticals Inc., Bayer Pharma AG, Merck & Cie. (Fahnestock, Derek) Modified on 7/22/2015 (nms). (Main Document 110 replaced on 7/22/2015) (nms). (Entered: 07/22/2015)
1112015-07-22 [SEALED] Corrected Post-Trial Response Brief, by Bayer HealthCare Pharmaceuticals Inc., Bayer Pharma AG, Merck & Cie. (Attachments: # 1 Exhibits A-B)(Fahnestock, Derek) Modified on 7/22/2015 (nms). (Entered: 07/22/2015)
1122015-07-28 REDACTED VERSION of 106 POST Trial Brief, by Watson Laboratories Inc.. (Attachments: # 1 Exhibits A-B)(Moore, David) Modified on 7/28/2015 (nms). (Entered: 07/28/2015)
1132015-08-03 REDACTED VERSION of 110 Exhibit to a Document, by Bayer HealthCare Pharmaceuticals Inc., Bayer Pharma AG. (Fahnestock, Derek) Modified on 8/4/2015 (nms). (Entered: 08/03/2015)
1142015-08-03 REDACTED VERSION of 111 Corrected POST Trial Brief, by Bayer HealthCare Pharmaceuticals Inc., Bayer Pharma AG. (Attachments: # 1 Exhibits A-B)(Fahnestock, Derek) Modified on 8/4/2015 (nms). (Entered: 08/03/2015)
1152015-08-31 Trial Opinion. Watson did not prove by clear and convincing evidence that claim 4 of the '168 patent is invalid. Merck is directed to submit an agreed upon final judgment within two weeks. Signed by Judge Richard G. Andrews on 8/31/2015. Associated Cases: 1:13-cv-00978-RGA, 1:13-cv-01272-RGA(nms) (Entered: 08/31/2015)
1162015-09-14 PROPOSED Final Judgment, by Bayer HealthCare Pharmaceuticals Inc., Bayer Pharma AG, Merck & Cie. (Attachments: # 1 Letter)(Fahnestock, Derek) Modified on 9/14/2015 (nms). (Entered: 09/14/2015)
1172015-09-14 FINAL JUDGMENT (CASE CLOSED). Signed by Judge Richard G. Andrews on 9/14/2015. (nms) (Entered: 09/14/2015)
1182015-09-15 Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 6,441,168 B1. (Attachments: # 1 Judgment)(nms) (Entered: 09/15/2015)
1192015-09-21 NOTICE OF APPEAL to the Federal Circuit of 117 Judgment, 115 Opinion, . Appeal filed by Watson Laboratories Inc.. (Moore, David) (Entered: 09/21/2015)
1202015-09-24 NOTICE of Docketing Record on Appeal from USCA for the Federal Circuit re 119 Notice of Appeal (Federal Circuit), filed by Watson Laboratories Inc.. USCA Case Number 15-2063. (nms) (Entered: 09/24/2015)
1212015-10-05 TRANSCRIPT REQUEST by Watson Laboratories Inc. TRANSCRIPT NOT NEEDED (Moore, David) (Entered: 10/05/2015)
1222016-07-29 Unopposed Motion To Vacate Final Judgments In Light Of Federal Circuit Mandate And For Expedited Consideration - filed by Watson Laboratories Inc.. (Attachments: # 1 Proposed Order, # 2 Exhibits A-F)(Moore, David) Modified on 8/6/2016 (nms). (Entered: 07/29/2016)
1232016-07-29 MANDATE of USCA as to 119 Notice of Appeal (Federal Circuit), filed by Watson Laboratories Inc.. USCA Decision: Reversed. (Attachments: # 1 Opinion and Judgment)(nms) (Entered: 08/06/2016)
1242016-08-08 ORDER Granting (122 in 13-cv-1272-RGA, 122 in 13-cv-978-RGA) MOTION to Vacate Final Judgments In Light Of Federal Circuit Mandate And For Expedited Consideration, filed by Watson Laboratories Inc.. Signed by Judge Richard G. Andrews on 8/8/2016. Associated Cases: 1:13-cv-00978-RGA, 1:13-cv-01272-RGA(nms) (Entered: 08/08/2016)
1252016-08-08 ORAL ORDER: The parties should meet and confer, and submit an agreed upon form of judgment consistent with the record for the Court to enter. Ordered by Judge Richard G. Andrews on 8/8/2016. Associated Cases: 1:13-cv-00978-RGA, 1:13-cv-01272-RGA(nms) (Entered: 08/08/2016)
1262016-08-11 MOTION To Declare This Case "Exceptional" Under 35 U.S.C. Section 285 And To Award Attorneys' Fees - filed by Watson Laboratories Inc.. (Attachments: # 1 Proposed Order)(Moore, David) Modified on 8/15/2016 (nms). (Entered: 08/11/2016)
1272016-08-11 [SEALED] OPENING BRIEF in Support re 126 MOTION To Declare This Case "Exceptional" Under 35 U.S.C. Section 285 And To Award Attorneys' Fees, filed by Watson Laboratories Inc..Answering Brief/Response due date per Local Rules is 8/29/2016. (Moore, David) Modified on 8/15/2016 (nms). (Main Document 127 replaced on 8/30/2016) (nms). (Entered: 08/11/2016)
1282016-08-11 [SEALED] DECLARATION of Steven A. Maddox re 126 MOTION To Declare This Case "Exceptional" Under 35 U.S.C. Section 285 And To Award Attorneys' Fees, by Watson Laboratories Inc.. (Attachments: # 1 Exhibits 1-9, # 2 Exhibits 10-17, # 3 Exhibits 18-30)(Moore, David) Modified on 8/15/2016 (nms). (Entered: 08/11/2016)
1292016-08-16 Letter to The Honorable Richard G. Andrews from David E. Moore regarding case status/Proposed Forms of Judgment. (Attachments: # 1 Proposed Judgment 13cv978-RGA, # 2 Proposed Judgment 13cv1272-RGA)(Moore, David) Modified on 8/17/2016 (nms). (Entered: 08/16/2016)
1302016-08-18 FINAL JUDGMENT in favor of Watson Laboratories Inc. against Bayer HealthCare Pharmaceuticals Inc., Bayer Pharma AG, Merck & Cie (CASE CLOSED). Signed by Judge Richard G. Andrews on 8/18/2016. (nms) (Entered: 08/18/2016)
1312016-08-18 REDACTED VERSION of 127 Opening Brief in Support, by Watson Laboratories Inc.. (Moore, David) Modified on 8/18/2016 (nms). (Main Document 131 replaced on 8/30/2016) (nms). (Entered: 08/18/2016)
1322016-08-18 REDACTED VERSION of 128 Declaration, by Watson Laboratories Inc.. (Attachments: # 1 Exhibits 1-9, # 2 Exhibits 10-17, # 3 Exhibits 18-30)(Moore, David) Modified on 8/18/2016 (nms). (Entered: 08/18/2016)
1332016-08-18 Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 6,441,168 B1. (Attachments: # 1 Final Judgment)(nms) (Entered: 08/18/2016)
1342016-08-29 ANSWERING BRIEF in Opposition re 126 MOTION To Declare This Case "Exceptional" Under 35 U.S.C. Section 285 And To Award Attorneys' Fees filed by Bayer HealthCare Pharmaceuticals Inc., Bayer Pharma AG, Merck & Cie.Reply Brief due date per Local Rules is 9/9/2016. (Blumenfeld, Jack) (Entered: 08/29/2016)
1352016-08-29 DECLARATION of Claudia Bernhardt re 134 Answering Brief in Opposition, by Bayer HealthCare Pharmaceuticals Inc., Bayer Pharma AG, Merck & Cie. (Blumenfeld, Jack) Modified on 8/30/2016 (nms). (Entered: 08/29/2016)
1362016-08-29 DECLARATION of Jack B. Blumenfeld re 134 Answering Brief in Opposition, by Bayer HealthCare Pharmaceuticals Inc., Bayer Pharma AG, Merck & Cie. (Blumenfeld, Jack) Modified on 8/30/2016 (nms). (Entered: 08/29/2016)
1372016-08-29 DECLARATION of Andreas Furger re 134 Answering Brief in Opposition, by Bayer HealthCare Pharmaceuticals Inc., Bayer Pharma AG, Merck & Cie. (Blumenfeld, Jack) Modified on 8/30/2016 (nms). (Entered: 08/29/2016)
1382016-08-29 DECLARATION of Rebecca T. Horwitz 134 Answering Brief in Opposition, by Bayer HealthCare Pharmaceuticals Inc., Bayer Pharma AG, Merck & Cie. (Blumenfeld, Jack) Modified on 8/30/2016 (nms). (Entered: 08/29/2016)
1392016-08-29 DECLARATION of Vera Katz re 134 Answering Brief in Opposition, by Bayer HealthCare Pharmaceuticals Inc., Bayer Pharma AG, Merck & Cie. (Blumenfeld, Jack) Modified on 8/30/2016 (nms). (Entered: 08/29/2016)
1402016-08-29 DECLARATION of J. Scott McBride re 134 Answering Brief in Opposition, by Bayer HealthCare Pharmaceuticals Inc., Bayer Pharma AG, Merck & Cie. (Blumenfeld, Jack) Modified on 8/30/2016 (nms). (Entered: 08/29/2016)
1412016-08-29 DECLARATION of Adam K. Mortara re 134 Answering Brief in Opposition, by Bayer HealthCare Pharmaceuticals Inc., Bayer Pharma AG, Merck & Cie. (Blumenfeld, Jack) Modified on 8/30/2016 (nms). (Entered: 08/29/2016)
1422016-08-29 DECLARATION of Dr. Rudolf Moser re 134 Answering Brief in Opposition, by Bayer HealthCare Pharmaceuticals Inc., Bayer Pharma AG, Merck & Cie. (Blumenfeld, Jack) Modified on 8/30/2016 (nms). (Entered: 08/29/2016)
1432016-08-29 DECLARATION of J. Scott McBride re 134 Answering Brief in Opposition, by Bayer HealthCare Pharmaceuticals Inc., Bayer Pharma AG, Merck & Cie. (Attachments: # 1 Exhibits A-Z, # 2 Exhibits AA-PP)(Blumenfeld, Jack) Modified on 8/30/2016 (nms). (Entered: 08/29/2016)
1442016-08-29 NOTICE of Lodging of Exhibit Y to the Declaration at D.I. 143 . The exhibit is in mulit-media format (disk), filed by Bayer HealthCare Pharmaceuticals Inc., Bayer Pharma AG, Merck & Cie (Blumenfeld, Jack) Modified on 8/30/2016 (nms). (Entered: 08/29/2016)
1452016-08-30 EXHIBIT Y (In Multi-Media format: Disk) re 143 Declaration, by Bayer HealthCare Pharmaceuticals Inc., Bayer Pharma AG, Merck & Cie. (see Notice of Lodging at D.I. 144 ). (nms) (Entered: 08/30/2016)
1462016-09-09 [SEALED] REPLY BRIEF re 126 MOTION To Declare This Case "Exceptional" Under 35 U.S.C. Section 285 And To Award Attorneys' Fees filed by Watson Laboratories Inc.. (O'Byrne, Stephanie) (Entered: 09/09/2016)
1472016-09-09 [SEALED] DECLARATION of Jeremy J. Edwards re 146 Reply Brief, by Watson Laboratories Inc.. (Attachments: # 1 Exhibits 31-43)(O'Byrne, Stephanie) Modified on 9/9/2016 (nms). (Entered: 09/09/2016)
1482016-09-12 Letter to The Honorable Richard G. Andrews from Jack B. Blumenfeld requesting oral argument and intent to seek leave to file sur-reply. (Blumenfeld, Jack) Modified on 9/12/2016 (nms). (Entered: 09/12/2016)
1492016-09-13 MOTION for Leave to File Surreply - filed by Bayer Pharma AG, Merck & Cie, Bayer HealthCare Pharmaceuticals Inc.. (Attachments: # 1 Exhibit A)(Fahnestock, Derek) Modified on 9/14/2016 (nms). (Entered: 09/13/2016)
1502016-09-15 REDACTED VERSION of 146 Reply Brief, by Watson Laboratories Inc.. (O'Byrne, Stephanie) Modified on 9/16/2016 (nms). (Entered: 09/15/2016)
1512016-09-15 REDACTED VERSION of 147 Declaration of Jeremy J. Edwards, by Watson Laboratories Inc.. (Attachments: # 1 Exhibits 31-43)(O'Byrne, Stephanie) Modified on 9/16/2016 (nms). (Entered: 09/15/2016)
1522016-09-19 ORAL ORDER: The Court will hear oral argument on the MOTION To Declare This Case "Exceptional" Under 35 U.S.C. Section 285 And To Award Attorneys' Fees (D.I. 126 ) on 11/1/2016, at 9:00 AM in Courtroom 6A before Judge Richard G. Andrews. Ordered by Judge Richard G. Andrews on 9/19/2016. Associated Cases: 1:13-cv-00978-RGA, 1:13-cv-01272-RGA(nms) (Entered: 09/19/2016)
1532016-09-22 Letter to The Honorable Richard G. Andrews from Derek J. Fahnestock regarding oral argument scheduled for November 1, 2016. (Attachments: # 1 Exhibits A-B)(Fahnestock, Derek) (Main Document 153 replaced on 9/22/2016) (nms). Modified on 9/22/2016 (nms). (Entered: 09/22/2016)
1542016-09-23 ORAL ORDER: Due to a scheduling conflict the hearing set for 11/1/2016, will be CONTINUED, and the hearing will now be held on 11/2/2016, at 10:00 AM in Courtroom 6A before Judge Richard G. Andrews. Ordered by Judge Richard G. Andrews on 9/23/2016. Associated Cases: 1:13-cv-00978-RGA, 1:13-cv-01272-RGA(nms) (Entered: 09/23/2016)
1552016-09-27 Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Teva Pharmaceuticals USA, Inc. for Watson Laboratories Inc. filed by Watson Laboratories Inc.. (O'Byrne, Stephanie) (Entered: 09/27/2016)
1562016-09-30 RESPONSE to 149 MOTION for Leave to File Surreply, filed by Watson Laboratories Inc.. (Moore, David) Modified on 10/3/2016 (nms). (Entered: 09/30/2016)
1572016-09-30 DECLARATION of Jeremy J. Edwards re 156 Response to Motion, by Watson Laboratories Inc.. (Attachments: # 1 Exhibits A-B)(Moore, David) Modified on 10/3/2016 (nms). (Entered: 09/30/2016)
1582016-10-11 REPLY BRIEF re 149 MOTION for Leave to File Surreply filed by Bayer HealthCare Pharmaceuticals Inc., Bayer Pharma AG, Merck & Cie. (Blumenfeld, Jack) (Entered: 10/11/2016)
1592016-11-02 ORAL ORDER: The Motion for Leave to File Surreply (D.I. 149 in 13-cv-978-RGA, D.I. 149 in 13-cv-1272-RGA) is GRANTED. Ordered by Judge Richard G. Andrews on 11/2/2016. Associated Cases: 13-cv-978-RGA, 13-cv-1272-RGA(nms) (Entered: 11/02/2016)
1602016-11-02 SUR-REPLY BRIEF re 126 MOTION To Declare This Case "Exceptional" Under 35 U.S.C. Section 285 And To Award Attorneys' Fees, filed by Bayer HealthCare Pharmaceuticals Inc., Bayer Pharma AG, Merck & Cie. (nms) Modified on 11/2/2016 (nms). (Entered: 11/02/2016)
1612016-11-02 [SEALED] DECLARATION, Volume 1 of 4 re 160 Sur-Reply Brief, by Bayer HealthCare Pharmaceuticals Inc., Bayer Pharma AG, Merck & Cie. (Attachments: # 1 part 1, # 2 part 2)(Fahnestock, Derek) Modified on 11/2/2016 (nms). (Entered: 11/02/2016)
1622016-11-02 [SEALED] DECLARATION, Volume 2 of 4 re 160 Sur-Reply Brief, by Bayer HealthCare Pharmaceuticals Inc., Bayer Pharma AG, Merck & Cie. (Attachments: # 1 Part 1, # 2 Part 2, # 3 Part 3)(Fahnestock, Derek) Modified on 11/2/2016 (nms). (Entered: 11/02/2016)
1632016-11-02 [SEALED] DECLARATION, Volume 3 of 4 re 160 Sur-Reply Brief, by Bayer HealthCare Pharmaceuticals Inc., Bayer Pharma AG, Merck & Cie. (Attachments: # 1 part 1, # 2 part 2)(Fahnestock, Derek) Modified on 11/2/2016 (nms). (Entered: 11/02/2016)
1642016-11-02 [SEALED] DECLARATION, Volume 4 of 4 re 160 Sur-Reply Brief, by Bayer HealthCare Pharmaceuticals Inc., Bayer Pharma AG, Merck & Cie. (Attachments: # 1 Part 1, # 2 Part 2, # 3 Part 3)(Fahnestock, Derek) Modified on 11/2/2016 (nms). (Entered: 11/02/2016)
1652016-11-02 Letter to Jack B. Blumenfeld, Esq. from Clerk, USDC/DE, dated 11/2/16, regarding return of Exhibit D.I. 145 Multimedia exhibit to a Document. (rwc) Modified on 11/2/2016 (nms). (Entered: 11/02/2016)
1662016-11-07 Official Transcript of Motion for Exceptional Case held on 11-02-16 before Judge Richard G. Andrews. Court Reporter/Transcriber Leonard A. Dibbs. Transcript may be viewed at the court public terminal or purchased through the Court Reporter/Transcriber before the deadline for Release of Transcript Restriction. After that date it may be obtained through PACER. Redaction Request due 11/28/2016. Redacted Transcript Deadline set for 12/8/2016. Release of Transcript Restriction set for 2/6/2017. (lad) (Entered: 11/07/2016)
1672016-11-09 REDACTED VERSION of 161 Declaration, Volume 1 of 4, by Bayer HealthCare Pharmaceuticals Inc., Bayer Pharma AG, Merck & Cie. (Attachments: # 1 Exhibits part 1, # 2 Exhibits part 2, # 3 Exhibits part 3)(Fahnestock, Derek) Modified on 11/9/2016 (nms). (Entered: 11/09/2016)
1682016-11-09 REDACTED VERSION of 162 Declaration, Volume 2 of 4, by Bayer HealthCare Pharmaceuticals Inc., Bayer Pharma AG, Merck & Cie. (Attachments: # 1 Exhibits part 1, # 2 Exhibits part 2, # 3 Exhibits part 3)(Fahnestock, Derek) Modified on 11/9/2016 (nms). (Entered: 11/09/2016)
1692016-11-09 REDACTED VERSION of 163 Declaration, Volume 3 of 4, by Bayer HealthCare Pharmaceuticals Inc., Bayer Pharma AG, Merck & Cie. (Attachments: # 1 Exhibits 22-37)(Fahnestock, Derek) Modified on 11/9/2016 (nms). (Entered: 11/09/2016)
1702016-11-09 REDACTED VERSION of 164 Declaration, Volume 4 of 4, by Bayer HealthCare Pharmaceuticals Inc., Bayer Pharma AG, Merck & Cie. (Attachments: # 1 Exhibits part 1, # 2 Exhibits part 2, # 3 Exhibits part 3)(Fahnestock, Derek) Modified on 11/9/2016 (nms). (Entered: 11/09/2016)
1712016-11-10 ACKNOWLEDGMENT OF RECEIPT of 145 Multi-media document. (rwc) (Entered: 11/10/2016)
1722016-11-16 [SEALED] Letter to The Honorable Richard G. Andrews from Derek J. Fahnestock regarding case status. (Fahnestock, Derek) (Entered: 11/16/2016)
1732016-11-18 [SEALED] Letter to The Honorable Richard G. Andrews from Derek J. Fahnestock regarding update on the parties' "exceptional" case discussions. (Fahnestock, Derek) (Entered: 11/18/2016)
1742016-11-28 REDACTED VERSION of 172 Letter, by Bayer HealthCare Pharmaceuticals Inc., Bayer Pharma AG, Merck & Cie. (Fahnestock, Derek) Modified on 11/28/2016 (nms). (Entered: 11/28/2016)
1752016-11-29 [SEALED] Letter to The Honorable Richard G. Andrews from Derek J. Fahnestock regarding further update on "exceptional" case discussions. (Fahnestock, Derek) Modified on 11/29/2016 (nms). (Entered: 11/29/2016)
1762016-11-30 REDACTED VERSION of 173 Letter, by Bayer HealthCare Pharmaceuticals Inc., Bayer Pharma AG, Merck & Cie. (Fahnestock, Derek) Modified on 11/30/2016 (nms). (Entered: 11/30/2016)
1772016-12-06 REDACTED VERSION of 175 Letter, by Bayer HealthCare Pharmaceuticals Inc., Bayer Pharma AG, Merck & Cie. (Fahnestock, Derek) Modified on 12/6/2016 (nms). (Entered: 12/06/2016)
1782016-12-06 [SEALED] Letter to The Honorable Richard G. Andrews from Derek J. Fahnestock. (Fahnestock, Derek) (Entered: 12/06/2016)
1792016-12-09 [SEALED] Letter to The Honorable Richard G. Andrews from Derek J. Fahnestock regarding Status Update - re (176 in 1:13-cv-01272-RGA) Letter. (Fahnestock, Derek) (Entered: 12/09/2016)
1802016-12-12 REDACTED VERSION of 178 Letter, by Bayer HealthCare Pharmaceuticals Inc., Bayer Pharma AG, Merck & Cie. (Fahnestock, Derek) Modified on 12/12/2016 (nms). (Entered: 12/12/2016)
1812016-12-12 REDACTED VERSION of 179 Letter, by Bayer HealthCare Pharmaceuticals Inc., Bayer Pharma AG, Merck & Cie. (Fahnestock, Derek) Modified on 12/12/2016 (nms). (Entered: 12/12/2016)
1822016-12-14 [SEALED] Letter to The Honorable Richard G. Andrews from Derek J. Fahnestock. (Fahnestock, Derek) (Entered: 12/14/2016)
1832016-12-16 [SEALED] Letter to The Honorable Richard G. Andrews from David E. Moore, Esquire regarding Motion To Declare This Case "Exceptional" and Attorneys' Fees. (Moore, David) (Entered: 12/16/2016)
1842016-12-19 ORAL ORDER: The request found in the letter filed on 12/16/2016, is GRANTED. Signed by Judge Richard G. Andrews on 12/19/2016. Associated Cases: 1:13-cv-00978-RGA, 1:13-cv-01272-RGA(nms) (Entered: 12/19/2016)
1852016-12-27 NOTICE of Withdrawal 126 MOTION To Declare This Case "Exceptional" Under 35 U.S.C. Section 285 And To Award Attorneys' Fees, by Watson Laboratories, Inc.. (O'Byrne, Stephanie) Modified on 12/28/2016 (nms). (Entered: 12/27/2016)
1862016-12-29 REDACTED VERSION of 182 Letter, by Bayer HealthCare Pharmaceuticals Inc., Bayer Pharma AG, Merck & Cie. (Fahnestock, Derek) Modified on 12/29/2016 (nms). (Entered: 12/29/2016)
1872016-12-29 REDACTED VERSION of 183 Letter, by Watson Laboratories Inc.. (Moore, David) Modified on 12/29/2016 (nms). (Entered: 12/29/2016)